Fewer Than 800 Scots Get NHS Weight Jabs

Fewer than 800 individuals in Scotland have received weight loss injections on the NHS, a stark contrast to the surge in private prescriptions for medications like Wegovy and Mounjaro. As of September 2026, only 705 patients had received these jabs for weight management. This limited availability stems from fewer than half of Scotland's health boards offering the treatment, often only within small pilot programs.

Leading medical professionals describe this disparity as discriminatory, arguing it exacerbates existing health inequalities. While medications like Mounjaro and Wegovy have been available for type 2 diabetes for years, their specific approval for weight loss in Scotland occurred in 2023 and 2024. An estimated 300,000 people are accessing these drugs privately, raising concerns about safe prescribing practices outside of professional oversight.

The Scottish government states that obesity medications are part of a broader treatment spectrum, with health boards deciding on availability. Despite obesity affecting a third of Scots and leading to serious health issues, routine NHS prescription for weight loss remains uncommon. Some health boards are exploring future access, but current pilot schemes, like the one in NHS Forth Valley, have strict eligibility criteria and are not accepting new referrals.

Doctors emphasize that these GLP-1 injections suppress appetite and can be effective, but require a comprehensive approach including diet, exercise, and monitoring to maintain results. The significant gap between private and NHS access disproportionately affects lower-income individuals, further widening health inequalities in Scotland.